- Record: found
- Abstract: found
- Article: not found
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.
Michael C Heinrich
1 ,
Christopher L Corless ,
George D Demetri ,
Charles D Blanke ,
Margaret von Mehren ,
Heikki Joensuu ,
Laura S McGreevey ,
Chang-Jie Chen ,
Annick D Van den Abbeele ,
Brian J Druker ,
Beate Kiese ,
Burton Eisenberg ,
Peter J Roberts ,
Samuel Singer ,
Christopher D M Fletcher ,
Sandra Silberman ,
Sasa Dimitrijevic ,
Jonathan A Fletcher
Dec 01 2003
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Most gastrointestinal stromal tumors (GISTs) express constitutively activated mutant isoforms of KIT or kinase platelet-derived growth factor receptor alpha (PDGFRA) that are potential therapeutic targets for imatinib mesylate. The relationship between mutations in these kinases and clinical response to imatinib was examined in a group of patients with advanced GIST.